{"id":"weekly-cisplatin-with-rt","safety":{"commonSideEffects":[{"rate":"30-90%","effect":"Nausea and vomiting"},{"rate":"20-80%","effect":"Neutropenia"},{"rate":"10-50%","effect":"Anemia"},{"rate":"5-30%","effect":"Thrombocytopenia"},{"rate":"5-20%","effect":"Kidney damage"},{"rate":"5-10%","effect":"Hearing loss"},{"rate":"5-10%","effect":"Tinnitus"},{"rate":"5-10%","effect":"Peripheral neuropathy"}]},"_chembl":{"chemblId":"CHEMBL197201","moleculeType":"Small molecule","molecularWeight":"520.35"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This leads to cell death, particularly in rapidly dividing cancer cells. Cisplatin also induces apoptosis and can cause DNA damage, further contributing to its anticancer effects.","oneSentence":"Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:41:00.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Ovarian cancer"},{"name":"Testicular cancer"},{"name":"Bladder cancer"},{"name":"Stomach cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT03811015","phase":"PHASE3","title":"Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-08-16","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":636},{"nctId":"NCT06770582","phase":"PHASE2","title":"Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-03","conditions":"Non-Muscle Invasive Bladder Urothelial Carcinoma, Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage I Bladder Cancer AJCC v8","enrollment":160},{"nctId":"NCT05172245","phase":"PHASE1","title":"Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-09-19","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Carcinoma of Unknown Primary, Locally Advanced Head and Neck Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT07195734","phase":"PHASE2","title":"Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-10-09","conditions":"Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":180},{"nctId":"NCT03952585","phase":"PHASE2, PHASE3","title":"De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-09","conditions":"Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":384},{"nctId":"NCT07061977","phase":"PHASE3","title":"Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-05","conditions":"Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma","enrollment":336},{"nctId":"NCT03775265","phase":"PHASE3","title":"Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-03","conditions":"Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8","enrollment":475},{"nctId":"NCT06323460","phase":"PHASE2","title":"Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer","status":"RECRUITING","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2024-03-21","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma","enrollment":45},{"nctId":"NCT03410615","phase":"PHASE2","title":"Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2018-05-28","conditions":"Oropharyngeal Squamous Cell Carcinoma","enrollment":129},{"nctId":"NCT03493425","phase":"PHASE2","title":"Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-03-12","conditions":"Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7","enrollment":82},{"nctId":"NCT02734537","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2016-11-23","conditions":"Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT04430699","phase":"PHASE2","title":"Cisplatin+Pembrolizumab+RT in Vulvar Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2020-07-29","conditions":"Vulvar Cancer, Vulvar Squamous Cell Carcinoma","enrollment":24},{"nctId":"NCT01810913","phase":"PHASE2, PHASE3","title":"Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-03-22","conditions":"Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7","enrollment":613},{"nctId":"NCT05050162","phase":"PHASE2, PHASE3","title":"Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer","status":"SUSPENDED","sponsor":"NRG Oncology","startDate":"2022-02-01","conditions":"Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma, Advanced Laryngeal Squamous Cell Carcinoma","enrollment":1714},{"nctId":"NCT07441681","phase":"PHASE3","title":"Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin","status":"NOT_YET_RECRUITING","sponsor":"NRG Oncology","startDate":"2027-01-06","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":454},{"nctId":"NCT07039162","phase":"PHASE2","title":"Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Ming-Yu Lien","startDate":"2025-09-26","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer","enrollment":45},{"nctId":"NCT05386550","phase":"PHASE3","title":"Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2022-10-06","conditions":"Head and Neck Cancer","enrollment":166},{"nctId":"NCT07415681","phase":"PHASE2","title":"GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries","status":"NOT_YET_RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2026-03","conditions":"Gynaecologic Cancer, Cervical Cancer, Radiation Therapy","enrollment":116},{"nctId":"NCT03258554","phase":"PHASE2, PHASE3","title":"Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-04-03","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma","enrollment":196},{"nctId":"NCT07097142","phase":"PHASE3","title":"Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2026-05-11","conditions":"Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8","enrollment":486},{"nctId":"NCT06532279","phase":"PHASE2","title":"Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2024-12-16","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":98},{"nctId":"NCT03323463","phase":"PHASE2","title":"Major De-escalation to 30 Gy for Select Human Papillomavirus Associated Oropharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-10-16","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Neck","enrollment":316},{"nctId":"NCT01154920","phase":"PHASE2","title":"Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-07-09","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":128},{"nctId":"NCT02567422","phase":"PHASE1","title":"Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-17","conditions":"Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7","enrollment":43},{"nctId":"NCT02066220","phase":"PHASE2, PHASE3","title":"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2014-06","conditions":"Brain Tumors","enrollment":360},{"nctId":"NCT06706401","phase":"PHASE3","title":"Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2025-02-20","conditions":"Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer","enrollment":460},{"nctId":"NCT02595879","phase":"PHASE1","title":"Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-09-18","conditions":"Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Cervical Squamous Cell Carcinoma","enrollment":21},{"nctId":"NCT04169763","phase":"PHASE1","title":"Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-07","conditions":"Stage II Vulvar Cancer AJCC v8, Stage III Vulvar Cancer AJCC v8, Stage IIIA Vulvar Cancer AJCC v8","enrollment":25},{"nctId":"NCT04580771","phase":"PHASE2","title":"A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-10-14","conditions":"Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018","enrollment":22},{"nctId":"NCT06056310","phase":"PHASE1","title":"Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)","status":"TERMINATED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2024-01-18","conditions":"Head and Neck Cancer","enrollment":18},{"nctId":"NCT01326468","phase":"NA","title":"Torisel in Addition to Standard Chemotherapy With Radiation for Advanced Head and Neck Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2011-12-08","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT02788461","phase":"NA","title":"Assessing the Efficacy and Safety of Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-Small Cell Lung Cancer Receiving Definitive Chemoradiotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2016-05","conditions":"Non-Small Cell Lung Cancer","enrollment":78},{"nctId":"NCT06865339","phase":"PHASE2","title":"Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Nitin Ohri","startDate":"2025-08-07","conditions":"NSCLC, Locally Advanced","enrollment":76},{"nctId":"NCT03070366","phase":"PHASE2","title":"Stereotactic Radiotherapy Combined With Chemotherapy or Not for Treatment of Oligometastases in HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2015-09-21","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":78},{"nctId":"NCT04900623","phase":"PHASE2","title":"Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study","status":"RECRUITING","sponsor":"Jonathan Schoenfeld, MD, MPH","startDate":"2021-07-02","conditions":"HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage","enrollment":145},{"nctId":"NCT06545747","phase":"PHASE3","title":"Adaptive Hypofractionated Radiotherapy for Locally Advanced NSCLC Based on Dynamic Enhanced MRI","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-01","conditions":"Non-small Cell Lung Cancer","enrollment":490},{"nctId":"NCT05388773","phase":"PHASE2","title":"Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer","status":"RECRUITING","sponsor":"Heath Skinner","startDate":"2022-07-20","conditions":"Oropharynx Cancer","enrollment":150},{"nctId":"NCT00392327","phase":"PHASE3","title":"Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2007-05-23","conditions":"Anaplastic Medulloblastoma, Medulloblastoma","enrollment":379},{"nctId":"NCT03612791","phase":"PHASE2","title":"Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab","status":"COMPLETED","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2018-08-13","conditions":"Locally Advanced Cervical Cancer","enrollment":189},{"nctId":"NCT06234748","phase":"PHASE2","title":"Trial of Individualized Adaptive RT in HPV-related High Risk Oropharynx Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2023-12-20","conditions":"Oropharynx Cancer, HPV-Related Carcinoma","enrollment":19},{"nctId":"NCT06093061","phase":"PHASE2","title":"Tislelizumab and Metronomic Capecitabine as Maintenance in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"National Cancer Centre, Singapore","startDate":"2024-07-03","conditions":"Nasopharyngeal Carcinoma","enrollment":69},{"nctId":"NCT05930938","phase":"PHASE3","title":"Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2023-12-12","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":19},{"nctId":"NCT02999087","phase":"PHASE3","title":"Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2017-09-14","conditions":"HNSCC","enrollment":707},{"nctId":"NCT03389477","phase":"PHASE2","title":"Los Tres Paso: Neoadjuvant Palbociclib Monotherapy, Concurrent Chemoradiation Therapy, Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-04-27","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":26},{"nctId":"NCT04091867","phase":"PHASE1","title":"sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-01-06","conditions":"Squamous Cell Carcinoma of Head and Neck","enrollment":3},{"nctId":"NCT02573493","phase":"PHASE2","title":"Nab-Paclitaxel and Cisplatin or Nab-paclitaxel as Induction Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck (HNSCC)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2016-04-13","conditions":"Squamous Cell Carcinoma of the Head and Neck, Carcinoma, Squamous Cell of the Head and Neck, Cancer of Head and Neck","enrollment":96},{"nctId":"NCT05800574","phase":"PHASE2","title":"Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2023-03-14","conditions":"Oropharynx Cancer","enrollment":22},{"nctId":"NCT03515538","phase":"PHASE2","title":"Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2018-07-12","conditions":"Oral Mucositis","enrollment":53},{"nctId":"NCT02516813","phase":"PHASE1","title":"Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-09-15","conditions":"Advanced Solid Tumors","enrollment":52},{"nctId":"NCT05203913","phase":"PHASE2","title":"Cisplatin, Nab-paclitaxel, Nivolumab With Radiotherapy After Resection of Non-Metastatic Muscle Invasive Bladder Cancer","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2023-05-01","conditions":"Muscle-Invasive Bladder Carcinoma","enrollment":32},{"nctId":"NCT06426056","phase":"PHASE2","title":"Nab-Paclitaxel Plus Cisplatin With Concurrent Radiotherapy for Patients With Locally Advanced Cervical Cancer: A Multicentre, Single-arm, Phase II Trial.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-06","conditions":"Cervical Cancer","enrollment":64},{"nctId":"NCT02072148","phase":"NA","title":"The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL)","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2014-03","conditions":"Human Papilloma Virus, Oropharyngeal Squamous Cell Carcinoma","enrollment":112},{"nctId":"NCT04212052","phase":"PHASE2","title":"Split-course Hypofractionated Radiotherapy With Concurrent Chemotherapy in Locally Advanced Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-07-01","conditions":"Non-small Cell Lung Cancer","enrollment":104},{"nctId":"NCT03345784","phase":"PHASE1","title":"Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-05-29","conditions":"Cervical Carcinoma, Endometrioid Adenocarcinoma, Malignant Female Reproductive System Neoplasm","enrollment":10},{"nctId":"NCT01588431","phase":"PHASE2","title":"Bevacizumab/Ph 2 for Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2011-12","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":3},{"nctId":"NCT02465736","phase":"PHASE3","title":"Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-07","conditions":"Esophageal Squamous Cell Carcinoma, Esophageal Cancer, Oesophageal Cancer","enrollment":610},{"nctId":"NCT02709720","phase":"PHASE2","title":"Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC","status":"COMPLETED","sponsor":"Spanish Lung Cancer Group","startDate":"2016-04-15","conditions":"Lung Cancer","enrollment":68},{"nctId":"NCT00957086","phase":"PHASE3","title":"Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2009-08-13","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":710},{"nctId":"NCT04951063","phase":"PHASE1","title":"Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2021-06-01","conditions":"Locally Advanced Lung Carcinoma","enrollment":18},{"nctId":"NCT04920344","phase":"PHASE2","title":"Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy","status":"UNKNOWN","sponsor":"Rutgers, The State University of New Jersey","startDate":"2021-07-19","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","enrollment":15},{"nctId":"NCT04989283","phase":"PHASE2","title":"Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2021-09-09","conditions":"Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":""},{"nctId":"NCT00096174","phase":"PHASE2","title":"Phase II Study of Concurrent C225, Cisplatin and Radiation in Stage IV Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2005-04-08","conditions":"Head and Neck Cancer","enrollment":69},{"nctId":"NCT04106362","phase":"PHASE2","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma","status":"TERMINATED","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2020-01-14","conditions":"Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, KRAS Protein Variant","enrollment":1},{"nctId":"NCT00492778","phase":"PHASE2","title":"Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer","status":"UNKNOWN","sponsor":"GOG Foundation","startDate":"2008-02-25","conditions":"Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation, Endometrial Mucinous Adenocarcinoma, Endometrial Squamous Cell Carcinoma","enrollment":165},{"nctId":"NCT00702481","phase":"PHASE2","title":"Study of Nimotuzumab and Cisplatin/Radiotherapy for Locally Advanced Head and Neck Squamous Cell Cancer","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2008-04-28","conditions":"Head and Neck Cancer","enrollment":32},{"nctId":"NCT03342378","phase":"","title":"PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2018-05-03","conditions":"Squamous Cell Carcinoma, Oropharynx Cancer","enrollment":24},{"nctId":"NCT01855451","phase":"PHASE3","title":"Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Trans Tasman Radiation Oncology Group","startDate":"2013-06-03","conditions":"HPV Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":189},{"nctId":"NCT00997906","phase":"PHASE2, PHASE3","title":"Cisplatin and RT With or Without Gemcitabine, Carboplatin, and Paclitaxel in Treating Patients With Locally Advanced NPC","status":"UNKNOWN","sponsor":"National Cancer Centre, Singapore","startDate":"2009-09-15","conditions":"Head and Neck Cancer","enrollment":172},{"nctId":"NCT04529850","phase":"PHASE2","title":"Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer","status":"COMPLETED","sponsor":"Galera Therapeutics, Inc.","startDate":"2020-06-30","conditions":"Head and Neck Cancer, Oral Mucositis","enrollment":38},{"nctId":"NCT00265941","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2005-11","conditions":"Head and Neck Cancer","enrollment":940},{"nctId":"NCT00655876","phase":"PHASE3","title":"Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2008-06","conditions":"Esophageal Cancer","enrollment":344},{"nctId":"NCT01889303","phase":"PHASE2","title":"Phase II Study of DC Versus 5-FU/CF as Chemotherapy and Concurrent Chemoradiotherapy for Locally Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Wuhan University","startDate":"2013-05","conditions":"Gastric Cancer","enrollment":100},{"nctId":"NCT01595061","phase":"PHASE2","title":"Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva","status":"UNKNOWN","sponsor":"Gynecologic Oncology Group","startDate":"2012-07-02","conditions":"Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7","enrollment":57},{"nctId":"NCT02289807","phase":"NA","title":"Concurrent Chemotherapy in Intermediate Risk Patients Treated With Intensity-modulated Radiotherapy","status":"WITHDRAWN","sponsor":"Sun Yat-sen University","startDate":"2015-03","conditions":"Nasopharyngeal Carcinoma","enrollment":""},{"nctId":"NCT04607642","phase":"PHASE2","title":"Trial of BMX-001 or Placebo in Head and Neck Cancer Patients","status":"WITHDRAWN","sponsor":"BioMimetix JV, LLC","startDate":"2021-07","conditions":"Head and Neck Cancer","enrollment":""},{"nctId":"NCT01674842","phase":"PHASE1","title":"Cisplatin + RT for Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2012-10","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT02768558","phase":"PHASE3","title":"Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC","status":"TERMINATED","sponsor":"RTOG Foundation, Inc.","startDate":"2016-10-17","conditions":"Non-Small Cell Lung Cancer","enrollment":20},{"nctId":"NCT02577341","phase":"PHASE2","title":"Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08","conditions":"Non-small-cell Lung Cancer","enrollment":122},{"nctId":"NCT01107639","phase":"PHASE3","title":"Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-05-27","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer","enrollment":297},{"nctId":"NCT04414566","phase":"PHASE3","title":"Induction Chemotherapy Plus Radiotherapy Alone in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2020-06-01","conditions":"Nasopharyngeal Carcinoma","enrollment":562},{"nctId":"NCT02938273","phase":"PHASE1","title":"Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-01","conditions":"Carcinoma, Squamous Cell of Head and Neck","enrollment":10},{"nctId":"NCT00806117","phase":"PHASE3","title":"Comparison of Different Subsequent Treatments After Radical Surgery","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2008-02-25","conditions":"Cervical Cancer","enrollment":1080},{"nctId":"NCT01561586","phase":"PHASE3","title":"Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Korea Cancer Center Hospital","startDate":"2012-03","conditions":"Cervical Cancer","enrollment":374},{"nctId":"NCT00828386","phase":"PHASE3","title":"Induction Chemotherapy and Chemoradiotherapy in Nasopharyngeal Cancers","status":"TERMINATED","sponsor":"Groupe Oncologie Radiotherapie Tete et Cou","startDate":"2009-01","conditions":"Nasopharyngeal Cancers","enrollment":83},{"nctId":"NCT00882583","phase":"PHASE1","title":"A Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in HNSCC","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2009-07","conditions":"Head and Neck Cancer","enrollment":22},{"nctId":"NCT03671265","phase":"NA","title":"Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-09-17","conditions":"Esophageal Cancer","enrollment":20},{"nctId":"NCT02633202","phase":"PHASE3","title":"Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2015-11","conditions":"Nasopharyngeal Carcinoma","enrollment":338},{"nctId":"NCT00084318","phase":"PHASE2","title":"Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2004-04","conditions":"Head and Neck Cancer","enrollment":238},{"nctId":"NCT02741856","phase":"PHASE2, PHASE3","title":"Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation","status":"UNKNOWN","sponsor":"Lisette Nixon","startDate":"2016-11-04","conditions":"Oesophageal Cancer","enrollment":584},{"nctId":"NCT01218048","phase":"PHASE2","title":"ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Robert Ferris","startDate":"2011-02","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":40},{"nctId":"NCT03366883","phase":"PHASE3","title":"Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02-01","conditions":"Esophageal Cancer Stage IIB, Esophageal Cancer Stage III","enrollment":420},{"nctId":"NCT01593475","phase":"PHASE2","title":"Induction Chemotherapy With Gemcitabine and Cisplatin Followed by CCRT for Unresectable Pancreatic Carcinoma","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2011-09-05","conditions":"Pancreatic Carcinoma Non-resectable","enrollment":44},{"nctId":"NCT00360971","phase":"PHASE3","title":"Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer","status":"TERMINATED","sponsor":"Radiation Therapy Oncology Group","startDate":"2006-07","conditions":"Head and Neck Cancer, Mucositis, Pain","enrollment":21},{"nctId":"NCT00066222","phase":"PHASE2","title":"Cisplatin, Etoposide, and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2003-06","conditions":"Lung Cancer","enrollment":72},{"nctId":"NCT03331575","phase":"PHASE3","title":"Hypofractionated vs. Conventionally Fractionated Concurrent CRT for Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2017-11","conditions":"Unresectable Stage III Non-small-cell Lung Cancer","enrollment":480},{"nctId":"NCT00999700","phase":"PHASE3","title":"Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin","status":"UNKNOWN","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2009-09","conditions":"Squamous Cell Carcinoma of the Head and Neck","enrollment":282},{"nctId":"NCT00017004","phase":"PHASE3","title":"Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia","status":"COMPLETED","sponsor":"Gynecologic Oncology Group","startDate":"2001-08","conditions":"Anemia, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma","enrollment":114},{"nctId":"NCT03053856","phase":"PHASE2","title":"Adjuvant Pembrolizumab in N2 Positive Non-small Cell Lung Cancer Patients","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2017-02-14","conditions":"Stage IIIA Non-small Cell Lung Cancer","enrollment":37},{"nctId":"NCT01540136","phase":"PHASE3","title":"Concurrent Chemoradiotherapy With Nedaplatin Versus Cisplatin in Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2012-02","conditions":"Nasopharyngeal Carcinoma","enrollment":402},{"nctId":"NCT00101582","phase":"PHASE3","title":"Palifermin for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Swedish Orphan Biovitrum","startDate":"2005-08","conditions":"Mucositis, Solid Tumors, Stomatitis","enrollment":188}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":65,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cisplatin"],"phase":"phase_3","status":"active","brandName":"Weekly cisplatin with RT","genericName":"Weekly cisplatin with RT","companyName":"Korea Cancer Center Hospital","companyId":"korea-cancer-center-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Non-small cell lung cancer, Ovarian cancer, Testicular cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}